Karyopharm Therapeutics (KPTI) PT Lowered to $43 at RBC Capital
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- Nasdaq futures slip on chip weakness; S&P 500 holds gains
- Massive market rotation raises question: Is the sell-AI trade here to stay?
- Goldman sees major AI and data center policy implications from ‘blue tsunami’
- Nvidia chips stockpile in Hong Kong awaits China import approval - report
- Goldman says this FX trade is the best hedge for the AI drawdown
Tweet
Share
E-mailGet Alerts KPTI Hot Sheet
Price: $0.07 --0%
Rating Summary:
10 Buy, 7 Hold, 1 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 20 | Down: 34 | New: 6
Rating Summary:
10 Buy, 7 Hold, 1 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 20 | Down: 34 | New: 6
Join SI Premium – FREE
RBC Capital analyst Brian Abrahams lowered the price target on Karyopharm Therapeutics (NASDAQ: KPTI) to $43.00 (from $45.00) while maintaining a Outperform rating.
You May Also Be Interested In
- Rodman & Renshaw Downgrades Karyopharm Therapeutics (KPTI) to Neutral
- Karyopharm files for Chapter 11, names Ayrmid as merger partner
- Everus (ECG) PT Lowered to $132 at DA Davidson
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
